4D Molecular Therapeutics, Inc. Operating Cash Flow
4D Molecular Therapeutics, Inc. (FDMT) reported Operating Cash Flow of -$138.12 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$70.00M.
- 4D Molecular Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$68.13M.
- 4D Molecular Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $28.55M.
- 4D Molecular Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$46.50M.
- 4D Molecular Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$109.08M.
- 4D Molecular Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$134.59M.
- 4D Molecular Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$75.79M.
- 4D Molecular Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$86.69M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$70.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$138.12M 10-Q · filed 2026-08-13 | -$109.57M derived: sum of 3 quarters · filed 2026-08-13 | -$156.07M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$68.13M 10-Q · filed 2026-05-07 | -$39.57M derived: sum of 2 quarters · filed 2026-05-07 | -$86.07M derived: sum of 3 quarters · filed 2026-05-07 | -$129.45M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $28.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$17.95M derived: sum of 2 quarters · filed 2026-03-18 | -$61.32M derived: sum of 3 quarters · filed 2026-08-13 | -$109.08M 10-K · filed 2026-03-18 |
| 2025-09-30 | -$46.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$89.88M derived: sum of 2 quarters · filed 2026-08-13 | -$137.63M 10-Q · filed 2025-11-10 | -$183.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$43.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$91.14M 10-Q · filed 2026-08-13 | -$137.00M derived: sum of 3 quarters · filed 2026-08-13 | -$166.39M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$47.76M 10-Q · filed 2026-05-07 | -$93.62M derived: sum of 2 quarters · filed 2026-05-07 | -$123.01M derived: sum of 3 quarters · filed 2026-05-07 | -$153.25M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$45.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$75.25M derived: sum of 2 quarters · filed 2026-03-18 | -$105.50M derived: sum of 3 quarters · filed 2026-03-18 | -$134.59M 10-K · filed 2026-03-18 |
| 2024-09-30 | -$29.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$59.63M derived: sum of 2 quarters · filed 2025-11-10 | -$88.72M 10-Q · filed 2025-11-10 | -$113.37M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$30.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$59.33M 10-Q · filed 2025-08-11 | -$83.98M derived: sum of 3 quarters · filed 2025-08-11 | -$85.15M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$29.09M 10-Q · filed 2025-05-08 | -$53.74M derived: sum of 2 quarters · filed 2025-05-08 | -$54.91M derived: sum of 3 quarters · filed 2025-05-08 | -$76.97M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$24.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$25.82M derived: sum of 2 quarters · filed 2025-02-28 | -$47.89M derived: sum of 3 quarters · filed 2025-02-28 | -$75.79M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$23.24M derived: sum of 2 quarters · filed 2024-11-13 | -$51.14M 10-Q · filed 2024-11-13 | -$73.36M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$22.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$49.97M 10-Q · filed 2024-08-08 | -$72.19M derived: sum of 3 quarters · filed 2024-08-08 | -$93.20M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$27.91M 10-Q · filed 2024-05-09 | -$50.12M derived: sum of 2 quarters · filed 2024-05-09 | -$71.14M derived: sum of 3 quarters · filed 2024-05-09 | -$91.04M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$22.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$43.23M derived: sum of 2 quarters · filed 2024-02-29 | -$63.13M derived: sum of 3 quarters · filed 2024-02-29 | -$86.69M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$21.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$40.92M derived: sum of 2 quarters · filed 2023-11-09 | -$64.47M 10-Q · filed 2023-11-09 | -$86.31M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$19.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$43.45M 10-Q · filed 2023-08-09 | -$65.29M derived: sum of 3 quarters · filed 2023-08-09 | -$81.01M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$23.55M 10-Q · filed 2023-05-11 | -$45.39M derived: sum of 2 quarters · filed 2023-05-11 | -$61.11M derived: sum of 3 quarters · filed 2023-05-11 | -$77.31M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$21.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$37.56M derived: sum of 2 quarters · filed 2023-03-15 | -$53.76M derived: sum of 3 quarters · filed 2023-03-15 | -$69.13M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$15.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$31.93M derived: sum of 2 quarters · filed 2022-11-08 | -$47.30M 10-Q · filed 2022-11-08 | -$64.80M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$16.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$31.58M 10-Q · filed 2022-08-11 | -$49.08M derived: sum of 3 quarters · filed 2022-08-11 | -$62.45M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$15.37M 10-Q · filed 2022-05-12 | -$32.87M derived: sum of 2 quarters · filed 2022-05-12 | -$46.24M derived: sum of 3 quarters · filed 2022-05-12 | -$52.41M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$17.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$30.87M derived: sum of 2 quarters · filed 2022-03-28 | -$37.04M derived: sum of 3 quarters · filed 2022-03-28 | -$50.91M 10-K · filed 2022-03-28 |
| 2020-09-30 | -$13.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$19.54M derived: sum of 2 quarters · filed 2021-11-10 | -$33.41M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$6.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$20.04M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$13.87M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | -$36.71M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |